Company: HCTI
Filing Date: 2025-04-01
Form Type: S-1
Source: 0001213900-25-027277
Chunk: 34

Company: Healthcare Triangle, Inc.
Filing Date: 2025-04-01
Form: S-1
Chunk 34
---
 claimant is proper
in the circumstances because he or she has met the applicable standard of conduct set forth in the DGCL, nor an actual determination by
the Company (including its Board of Directors, legal counsel, or its stockholders) that the claimant has not met such applicable standard
of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.
Indemnification shall include payment by the Company of expenses in defending an action or proceeding in advance of the final disposition
of such action or proceeding upon receipt of an undertaking by the person indemnified to repay such payment if it is ultimately determined
that such person is not entitled to indemnification.

In any underwriting agreement we enter into in
connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions,
us, our directors, our officers, and persons who control us within the meaning of the Securities Act of 1933, as amended, or the Securities
Act, against certain liabilities.

Item 15. Recent Sales of Unregistered Securities

During the past three years, we issued the following
securities, which were not registered under the Securities Act.

Private Placement in March 2025

On February 27, 2025,
the Company entered into securities purchase agreements with several institutional investors (the “Investors”) for the private
placement of 36,190,485 units (each a, “Unit”), with each Unit consisting of one share of the Company’s common stock
(“Common Stock”) or one pre-funded warrant (a “Pre-Funded Warrant”) to purchase one share of Common Stock, one
Series A Warrant (a “Series A Warrant”) to purchase one share of common stock and one Series B Warrant (a “Series B
Warrant” and together with the Series A Warrant, the “Purchase Warrants”) to purchase one share of Common Stock at an
offering price of $0.42 per Unit (or $0.41999 per Unit in the case of Units that include pre-funded warrants), for gross proceeds of $15.2
million (excluding any related expenses and underwriting discounts).

The initial exercise price for both the Series
A Warrants and Series B Warrants is $0.84 per share and both terminate on the fifth anniversary of the later of (x) effective date of
stockholder approval and (y) the earlier of (